37 results about "Monoamine oxidase B" patented technology

The present invention provides for the identification, isolation and uses of mammalian Monoamine Oxidase C (MAO-C), also known as renalase.

The invention discloses a monoamine oxidase from Pseudomonas sp., a coding gene, a recombinant expression vector, a recombination expression transformant, and the synthesis application of the monoamine oxidase in tetrahydroquinoline chiral amine compounds. The coding gene of the monoamine oxidase MAO5-ZMU is from Pseudomonas sp. ZMU-T01. The amino acid sequence of monoamine oxidase protein is shown in SEQID No.1, and the corresponding coding gen nucleotide sequence is shown in SEQIDNo.2; the monoamine oxidase gene can be connected with an expression carrier to construct to obtain a recombination expression plasmid; the recombination expression plasmid is converted to escherichia coli to obtain genetically engineered bacteria with monoamine oxidase activity. The genetically engineered bacteria with monoamine oxidase activity can be used for effectively catalyzing 2-methyl-1,2,3,4-tetrahydroquinoline compounds for oxidation splitting, has the characteristics of high selectivity, moderatereaction condition, environment protection and the like and can be used for the biosynthesis of the chiral tetrahydroquinoline compounds.

The invention provides a monoamine oxidase with high catalysis activity, strong enantioselectivity and good substrate survivability, and an enzyme-chemical synthesis method using the above enzyme to carry out enzyme catalyzed synthesis of (1S,2S,5R)-6,6-dimethyl-2-substituted-3-azabicyclo[3.1.0]hexane or (1S,3aR,6aS)-1-substituted-octahydrocyclopenta[c]pyrrole in order to further synthesize (1S,2S,5R)-6,6-dimethyl-2-3-azabicyclo[3.1.0]hexane-2-nitrile and its hydrolysate methyl (1S,2S,5R)-6,6-dimethyl-2-3-azabicyclo[3.1.0]hexane-2-carboxylate or further synthesize (1S,3aR,6aS)-1-octahydrocyclopenta[c]pyrrole-1nitrile The invention also provides a gene for coding the monoamine oxidase, a recombinant expression vector containing the gene, a recombinant expression transformant containing the gene, and efficient preparation methods of the vector and the transformant. The monoamine oxidase can respectively react with 3-5 and 5-5 azacyclopentamine systems with different sizes to generate corresponding imides; the imides undergo cyanide addition, so a cyanide is added to an enzyme catalysis system, and the above obtained addition product can be directly alcoholyzed in a hydrochloric acid-alcohol solution to obtain hydrochloride of amino acid methyl ester, so one-pot feeding is realized, the reaction technology is simplified, and industrial production is facilitated.

The invention relates to the application of a calcium disodium edentate and corticosteroid compound preparation in preparing medicine capable of inhibiting connective tissue growth factors and monoamine oxidase, and provides a compound preparation prepared from calcium disodium edentate and corticosteroid, which comprises the calcium disodium edentate which serves as the active component, the corticosteroid and one or more medicinal auxiliary ingredients; and the compound preparation contains the calcium disodium edentate in the weight percentage of 2 to 20 percent, glucocorticoid in the weight percentage of 0.01 to 0.1 percent, and the auxiliary ingredients which can be used for injection.

The invention discloses a traditional Chinese medicine composition with an effect of inhibiting the activity of monoamine oxidase A and application thereof. The traditional Chinese medicine composition is prepared together from a composition of a Chinese angelica root raw medicinal material or extract thereof and a chuanxiong rhizome raw medicinal material or extract thereof, serving as an effective medicinal ingredient, with acceptable auxiliary additives in medicinal materials. The extract can be an alcohol solution extract, an aqueous solution extract or volatile oil. The traditional Chinese medicine composition can be independently used as a medicine for inhibiting the activity of monoamine oxidase A or used as a medicinal ingredient for inhibiting the activity of monoamine oxidase A to combine with other available medicinal ingredients in the field of medicines. The chuanxiong rhizomes and Chinese angelica roots respectively have the effect of inhibiting human monoamine oxidase A,and are combined to serve as the inhibitor of monoamine oxidase A due to the remarkable synergistic effect.

The invention relates measuring method of monoamine oxidase activity and its diagnostic kit, comprising the following steps: using the benzylamine, p-toluidine red-ª‰-azo naphthol, butyl amine, amyl amine, ª‰-phenylethylamine, tyramine and other aminated compounds as substrate, it reacted with monoamine oxidase to produce auricome, then auricome carried out coupling reaction with hydrogen peroxidase and aldehyde dehydrogenase, carrying out the reaction to turn the oxidation type coenzyme to reduction type coenzyme, detecting the ascending velocity of absorbance of main wavelength 340nm to reflect the activity of monoamine oxidase in sample by definite quantity. The method has high specificity, good accuracy. The diagnostic kit is made to double agents or tri-agent to reduce the across impact and keep the agent stability and be good for long term storage. The method can be rapidly detected by the ultra-violet / visible light analysis meter or semi-automatic / full-automatic biochemical analysis meter, so the method is easy to spread and use.

The present invention provides for the identification, isolation and uses of mammalian Monoamine Oxidase C (MAO-C), also known as renalase.

The invention discloses a traditional Chinese medicine mask. The traditional Chinese medicine mask is prepared from radix paeoniae alba, bletillae rhizome, rhizoma typhonii, aloe, rhizoma atractylodismacrocephalae, Chinese waxgourd seeds, sparrow drippings, white muscardine silkworm, radix angelicae, white poria, herba asari cum radice, radix arnebiae seu lithospermi, licorice root, borneol, peach kernels, chuanxiong rhizome, lithargyrum, fructus tribuli, radix ampelopsis, radix salviae miltiorrhizae, honey, mature vinegar, glutinous rice flour, talcum powder and mung bean flour. The traditional Chinese medicine mask has an obvious elimination effect on lipid peroxides of cell membranes, can antagonize the lipid peroxidation reaction of erythrocyte membranes caused by hydrogen peroxide and oxygen free radicals, has an effect of removing lipid peroxidation metabolites, can significantly reduce the activity of monoamine oxidase B in tissues, can reduce the accumulation of lipofuscin incells, can antagonize the generation of the oxygen free radicals and malondialdehyde, can improve the SOD activity, and can inhibit the activity of tyrosinase, prevent and eliminate facial melanin pigmentation, thereby preventing and eliminating skin freckles, dark spots and old age spots, removing freckles and acne, whitening, moisturizing and treating acne and plane warts.

The invention belongs to the technical field of biology, relates to genetic engineering, biotransformation, bioconversion and biological catalysis, and organic synthesis technology, and discloses a monoamine oxidase gene from Aspergillus albicans and application thereof in chiral amine intermediate preparation using the monoamine oxidase gene to catalyze asymmetric oxidation reaction. The monoamine oxidase AaMAO7-6 gene is 1527 bp and encodes monoamine oxidase formed by 509 amino acids. After the recombinant monoamine oxidase built by the monoamine oxidase gene is expressed, the whole-cell orenzyme is used for transforming cis-7-aza-bicyclo[3,3,0]octane to generate the key chiral intermediate of Telaprevir. The preparation method is mild in reaction conditions, high in stereoselectivity,easy to achieve industrialization and the like.

The invention belongs to the technical field of biology, relates to genetic engineering, biotransformation, bioconversion and biological catalysis, and organic synthesis technology, and discloses a monoamine oxidase gene from Aspergillus flavus and application thereof in chiral amine intermediate preparation using the monoamine oxidase gene to catalyze asymmetric oxidation reaction. The monoamineoxidase AaMAO7-6 gene is 1419 bp and encodes monoamine oxidase formed by 470 amino acids. After the recombinant monoamine oxidase built by the monoamine oxidase gene is expressed, the whole-cell or enzyme is used for transforming cis-7-aza-bicyclo[3,3,0]octane to generate the key chiral intermediate of Telaprevir. The preparation method is mild in reaction conditions, high in stereoselectivity, easy to achieve industrialization and the like.

The invention relates measuring method of monoamine oxidase activity and its diagnostic kit, comprising the following steps: using the benzylamine, p-toluidine red-ª‰-azo naphthol, butyl amine, amyl amine, ª‰-phenylethylamine, tyramine and other aminated compounds as substrate, it reacted with monoamine oxidase to produce aldehydes, then auricome carried out coupling reaction with aldehyde dehydrogenase, carrying out the reaction to turn the oxidation type coenzyme to reduction type coenzyme, detecting the ascending velocity of absorbance of main wavelength 340nm to reflect the activity of monoamine oxidase in sample by definite quantity. The method has high specificity and good accuracy. The diagnostic kit is made to double agents or tri-agent to reduce the across impact and keep the agent stability and be good for long term storage. The method can be rapidly detected by the ultra-violet / visible light analysis meter or semi-automatic / full-automatic biochemical analysis meter, so the method is easy to spread and use.

The invention provides application of Houttuynoid A for preparing a monoamine oxidase (MAO) inhibitor. Compared with the original MAO inhibitor, the inhibitory activity and the selectivity on MAO-A and MAO-B of the MAO inhibitor provided by the invention are greatly increased. The application of Houttuynoid A for preparing the MAO inhibitor is disclosed for the first time; because the skeleton type belongs to a brand new skeleton type and the MAO inhibitory activity of Houttuynoid A is strong unexpectedly, the possibility that other compounds give any inspiration does not exist; Houttuynoid A has outstanding substantive characteristics; and simultaneously, Houttuynoid A has obvious progress for treating diseases related to MAO imbalance.

The invention discloses a kit for measuring monoamine oxidase and a preparation method thereof. The kit comprises double liquid components including a reagent R1 and a reagent R2 independent of each other, wherein the reagent R1 comprises 50-150 mmol / L Tris buffer solution, 12-38 mmol / L benzylamine, 2-18 mmol / L alpha-ketoglutaric acid and 0.3-1.7 mmol / L EDTA, and the solvent is purified water; and the reagent R2 comprises 50-150 mmol / L Tris buffer solution, 0.5-2.5 mmol / L acetyl coenzyme A, 0.2-1.8 mmol / L reduced coenzyme and 0.5-3.5 KU / L glutamate dehydrogenase, and the solvent is purified water. The preparation method comprises the following steps: preparing the reagents according to the component contents; mixing a to-be-measured sample with the reagent R1 and reagent R2 for sufficient reaction; measuring the absorbance difference after reaction by a full-automatic biochemical analyzer; and calculating the concentration of monoamine oxidase in the sample according to the absorbance change. The kit and preparation method thereof disclosed by the invention have the advantages of convenient operation, high accuracy and the like.

The present invention relates to uses of 5-(3,4-methylenedioxy phenyl)-2E,4E pentadienoic acid propylamine amide in preparation of medicinal compositions for treatment and / or prevention of neuron diseases requiring neuroprotection effects and / or nerve regeneration. The 5-(3,4-methylenedioxy phenyl)-2E,4E pentadienoic acid propylamine amide provides good treatment effects for depressions caused by various causes, provides significant anti-depression activity for a pharmacological depression model, provides a good protection effect for SH-SY5Y cells damaged by glutamic acid, and provides a selective inhibition effect for monoamine oxidase B (MAO-B).

The invention relates to an application of Chukrasone A in preparing MAO (Monoamine Oxidase) inhibitor medicines. Compared with existing MAO inhibitors, the MAO inhibitor provided by the invention is greatly improved in inhibitory activity and selectivity to MAO-A and MAO-B. The use of the Chukrasone A for preparing MAO inhibitor medicines provided by the invention is disclosed for the first time. As the framework type belongs to a brand-new framework type, and the inhibitory activity of the Chukrasone A to MAO is unimaginably strong, the probability of giving any enlightenment by other compounds does not exist. The Chukrasone A has remarkable substantial characteristics and meanwhile has remarkable progress for treating diseases associated to MAO disorder.

The invention belongs to the technical field of drug screening, and discloses a monoamine oxidase A microreactor and a preparation method and application thereof. An amino group-containing magnetic nano material is mixed with a glutaraldehyde solution for activation reaction to obtain an activated magnetic nano material, and the monoamine oxidase A microreactor is prepared by mixing of the activated magnetic nano material and a pyridine solution in which monoamine oxidase A is dissolved for immobilization reaction, performing solid-liquid separation after the immobilization reaction is completed, and removing of supernatant. The monoamine oxidase A microreactor can be applied to screening of antidepressant active ingredients in natural products, has the advantages of simple operation and high automation, and can achieve high-throughput screening.

The invention provides application of Norsampsone B in preparing a MAO (monoamine oxidase) inhibitor, compared with the existing MAO inhibitor, the inhibitory activity and the selectivity of MAO-A and MAO-B of the Norsampsone B are greatly improved. The application of the Norsampsone B in preparing the MAO inhibitor is disclosed for the first time, and the inhibitory activity to the MAO is high, the Norsampsone B has outstanding substantive features, and obviously has remarkable improvement for treating diseases relevant to imbalance of the MAO at the same time.

The invention relates to the application of a calcium disodium edentate and corticosteroid compound preparation in preparing medicine capable of inhibiting connective tissue growth factors and monoamine oxidase, and provides a compound preparation prepared from calcium disodium edentate and corticosteroid, which comprises the calcium disodium edentate which serves as the active component, the corticosteroid and one or more medicinal auxiliary ingredients; and the compound preparation contains the calcium disodium edentate in the weight percentage of 2 to 20 percent, glucocorticoid in the weight percentage of 0.01 to 0.1 percent, and the auxiliary ingredients which can be used for injection.

The invention provides application of Gypensapogenin B to preparation of a MAO (monoamine oxidase) inhibitor. Compared with the existing MAO inhibitor, the MAO inhibitor provided by the invention has greatly improved inhibitory activity and selectivity on MAO-A and MAO-B. The application of Gypensapogenin B to preparation of the MAO inhibitor is firstly publicized; and as a framework type belongs to a brand-new framework type, the framework type has unexpectedly strong inhibitory activity on the MAO inhibitor without any possibility shown by other compounds, and has outstanding substantial characteristics and remarkable progress for treating the diseases related to MAO unbalance at the same time.

The invention described herein provides a fast dispersing oral solid dosage form containing monoamine oxidase B inhibitor (MAO-B inhibitor) as the active ingredient, and method of treating disease therewith, such as Parkinson's disease. In one embodiment, the monoamine oxidase B inhibitor selegiline or its analogue can be the sole active ingredient in the composition administered. The dosage form composition is formulated to promote absorption through the buccal, sublingual, pharyngeal and / or esophageal mucous membrane tissue, such that at least 5% of the active ingredient is absorbed within one minute of placement in the oral cavity, as determined by a buccal absorption test. Monoamine oxidase B inhibitor compounds administered in accordance with the invention decrease the amount of undesirable metabolites associated with first pass effect of selegiline, for example, such as amphetamine and methamphetamine. The invention provides a number of other advantages over conventional orally administered tablet forms, including administration of monoamine oxidase B inhibitor compounds to patients that have difficulty swallowing.

The invention discloses the application of fluevirosines A in preparation of a monoamine oxidase (MAO) inhibitor. Compared with an existing MAO inhibitor, the fluevirosines A has the advantages that the inhibitory activity and selectivity to MAO-A and MAO-B are improved greatly. The application of the fluevirosines A in preparation of the MAO inhibitor is disclosed for the first time. Besides, the fluevirosines A has the advantages of being high in inhibitory activity to the MAO and prominent in substantive features, and makes remarkable progress in treatment of diseases related to disorder of the MAO.

The invention discloses an efficient preparation method of fluorine [18F] safinamide and application of a PET (positron emission tomography) developer, and the method comprises the following steps: firstly, designing to prepare a precursor of the fluorine [18F] safinamide, and then realizing direct radioactive fluoro labeling on aromatic rings in the precursor through nucleophilic substitution reaction to obtain the fluorine [18F] safinamide. The precursor is Mel-SF, SPIAd-SF, SPI5-SF, Me3Sn-SF, or Bpin-SF, and the SF is SF or SF; the prepared fluorine [18F] safinamide can be used as a PET (Polyethylene Terephthalate) imaging agent for imaging a cell line capable of secreting monoamine oxidase B, can also be used for imaging living animals, can penetrate through a blood brain barrier and realize brain region imaging, can be reversibly combined with multiple target spots in vivo, can also be used for imaging animal in-vitro tissues, and can be applied to imaging of animal in-vitro tissues. The method has potential application prospects in the medical fields of medical early diagnosis, adjuvant therapy, pathogenesis research and the like.

The invention provides an application of Houttuynoid D in preparation of a monoamine oxidase (MAO) inhibitor. Compared with that of the existing MAO inhibitor, the inhibitory activity and selectivity on MAO-A and MAO-B are greatly improved. The application of Houttuynoid D in preparation of the MAO inhibitor is disclosed for the first time, and because the framework type belongs to a novel framework type, the inhibitory activity on the MAO is unexpectedly high, the possibility that other compounds give enlightenment is avoided, and the Houttuynoid D has outstanding substantial characteristics and has obvious progress in treatment of MAO disorder related diseases.

The invention belongs to the field of medicine, and particularly provides a monoamine oxidase (MAO) inhibitor and application thereof. The MAO inhibitor is composed of a compound Spirostane-type glycoside and excipients. Compared with existing MAO inhibitors, the MAO inhibitor has the advantages that both inhibiting activity and selectivity to MAO-A and MAO-B are improved greatly, application of Spirostane-type glycoside in preparating the MAO inhibitor is disclosed for the first time, and Spirostane-type glycoside is high in inhibiting activity to MAO, has protruding substantive characteristics and has remarkable progress obviously when being used for treating diseases related to MAO disorder.

The invention relates to a medicine for treating Alzheimer's disease, and belongs to the field of chemical medicines. The invention provides an acetylcholin esterase inhibitor which is used for preparing a medicine for treating Alzheimer's disease. The compound has the activity of relieving the Alzheimer's disease, plays a role in various ways of inhibiting acetylcholin esterase and monoamine oxidase B, resisting oxidation activity and the like, and can be used as a multi-target medicine for treating the Alzheimer's disease.